Citryll is a pharmaceutical company engaged in the treatment of autoimmune and other human diseases such as lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. It develops tACPA program, targeting the formation of neutrophil extracellular traps (NETs) to prevent or treat autoimmune diseases including rheumatoid arthritis.